gonyzyf.wordpress.com
Valentino was most recently president and CEO ofNew Jersey-basexd , which was acquired in 2008 by Britisj firm Reckett Benckiser. He has held managementt positions with majordrug companies, including Alpharma, Novartis, Pharmacia/Upjohn and Warner Lambert. Valentino replaces William who was named CEO of Xanodyne in 2004 and left the compangyin 2007. Xanodyne’s priorities will be to bringv to market its Zipsor acutepain treatment, and a drug in development for heavy menstrual Valentino said in a news release. The companyu also said it completed $38 million in equity financing, led by , a Boston-basef health care equity firm.
Other investors in the company includweAIG Investments’ sponsored funds, Aisling Capital, Blue Chip Venturr Co., Essex Woodlands, HealthCare Ventures LLC and Union “Mike brings major pharmaceutical and commercial experience to the team whil e the financing brings critical resources neede d for the launches,” said Rolf Classon, board chairman, in the Xanodyne, based in Newport, is a specialty pharmaceuticap company focused on treatments for women’ health care and pain management.
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment